These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20797593)

  • 1. Addition of a second LV pacing site in CRT nonresponders rationale and design of the multicenter randomized V(3) trial.
    Bordachar P; Alonso C; Anselme F; Boveda S; Defaye P; Garrigue S; Gras D; Klug D; Piot O; Sadoul N; Leclercq C
    J Card Fail; 2010 Sep; 16(9):709-13. PubMed ID: 20797593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of an additional left ventricular lead in cardiac resynchronization therapy nonresponders: The V
    Bordachar P; Gras D; Clementy N; Defaye P; Mondoly P; Boveda S; Anselme F; Klug D; Piot O; Sadoul N; Babuty D; Leclercq C
    Heart Rhythm; 2018 Jun; 15(6):870-876. PubMed ID: 29288035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
    J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study.
    Gasparini M; Bocchiardo M; Lunati M; Ravazzi PA; Santini M; Zardini M; Signorelli S; Passardi M; Klersy C;
    Am Heart J; 2006 Jul; 152(1):155.e1-7. PubMed ID: 16824846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure.
    Leclercq C; Gadler F; Kranig W; Ellery S; Gras D; Lazarus A; Clémenty J; Boulogne E; Daubert JC;
    J Am Coll Cardiol; 2008 Apr; 51(15):1455-62. PubMed ID: 18402900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac resynchronization therapy: device-based medicine for heart failure.
    Philippon F
    J Card Surg; 2004; 19(3):270-4. PubMed ID: 15151661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-site left ventricular cardiac resynchronization therapy.
    Padeletti L; Colella A; Michelucci A; Pieragnoli P; Ricciardi G; Porciani MC; Tronconi F; Hettrick DA; Valsecchi S
    Am J Cardiol; 2008 Dec; 102(12):1687-92. PubMed ID: 19064025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-site versus standard cardiac resynchronization therapy study (TRUST CRT): clinical rationale, design, and implementation.
    Lenarczyk R; Kowalski O; Sredniawa B; Pruszkowska-Skrzep P; Pluta S; Sokal A; Kukulski T; Stabryła-Deska J; Woźniak A; Kowalczyk J; Zielińska T; Mazurek M; Streb W; Zembala M; Kalarus Z
    J Cardiovasc Electrophysiol; 2009 Jun; 20(6):658-62. PubMed ID: 19635069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biventricular vs. left univentricular pacing in heart failure: rationale, design, and endpoints of the B-LEFT HF study.
    Leclercq C; Ansalone G; Gadler F; Boriani G; Perez-Castellano N; Grubb N; Sack S; Boulogne E
    Europace; 2006 Jan; 8(1):76-80. PubMed ID: 16627414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure.
    Mollema SA; Bleeker GB; van der Wall EE; Schalij MJ; Bax JJ
    Am J Cardiol; 2007 Dec; 100(11):1665-70. PubMed ID: 18036366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
    Pires LA; Abraham WT; Young JB; Johnson KM;
    Am Heart J; 2006 Apr; 151(4):837-43. PubMed ID: 16569543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of stimulation site on diastolic function in cardiac resynchronization therapy.
    de Cock CC; Vos DH; Jessurun E; Allaart CP; Visser CA
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S40-2. PubMed ID: 17302714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cardiac resynchronization therapy on the mechanisms underlying functional mitral regurgitation in congestive heart failure.
    Porciani MC; Macioce R; Demarchi G; Chiostri M; Musilli N; Cappelli F; Lilli A; Ricciardi G; Padeletti L
    Eur J Echocardiogr; 2006 Jan; 7(1):31-9. PubMed ID: 16378918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy.
    Bax JJ; Bleeker GB; Marwick TH; Molhoek SG; Boersma E; Steendijk P; van der Wall EE; Schalij MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1834-40. PubMed ID: 15519016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressure-volume loop analysis during implantation of biventricular pacemaker/cardiac resynchronization therapy device to optimize right and left ventricular pacing sites.
    Delnoy PP; Ottervanger JP; Luttikhuis HO; Vos DH; Elvan A; Ramdat Misier AR; Beukema WP; Steendijk P; van Hemel NM
    Eur Heart J; 2009 Apr; 30(7):797-804. PubMed ID: 19202156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure-volume loops.
    Steendijk P; Tulner SA; Bax JJ; Oemrawsingh PV; Bleeker GB; van Erven L; Putter H; Verwey HF; van der Wall EE; Schalij MJ
    Circulation; 2006 Mar; 113(10):1295-304. PubMed ID: 16520415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale.
    Martin DO; Stolen KQ; Brown S; Yu Y; Christie C; Doshi SK; Smith JM; Gold MR; Day JD
    Am Heart J; 2007 Jan; 153(1):7-13. PubMed ID: 17174627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold M; Abraham WT; Daubert JC;
    Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of left ventricular lead location on outcomes in the COMPANION study.
    Saxon LA; Olshansky B; Volosin K; Steinberg JS; Lee BK; Tomassoni G; Guarnieri T; Rao A; Yong P; Galle E; Leigh J; Ecklund F; Bristow MR
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):764-8. PubMed ID: 19298563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.